Zacks Research Brokers Reduce Earnings Estimates for IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities researchers at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for Iovance Biotherapeutics in a research note issued to investors on Tuesday, July 15th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings of ($0.22) per share for the quarter, down from their previous forecast of ($0.21). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.30) EPS.

A number of other equities research analysts have also issued reports on the company. Truist Financial lowered Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 12th. UBS Group cut Iovance Biotherapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $17.00 to $2.00 in a research note on Friday, May 16th. Mizuho dropped their price objective on Iovance Biotherapeutics from $30.00 to $10.00 and set an “outperform” rating on the stock in a research note on Monday, May 12th. HC Wainwright dropped their price objective on Iovance Biotherapeutics from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, The Goldman Sachs Group downgraded Iovance Biotherapeutics from a “neutral” rating to a “sell” rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $12.22.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ IOVA opened at $2.23 on Friday. The business’s 50 day moving average is $1.90 and its two-hundred day moving average is $3.65. Iovance Biotherapeutics has a 1-year low of $1.64 and a 1-year high of $12.51. The stock has a market capitalization of $744.67 million, a P/E ratio of -1.80 and a beta of 0.85.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.11). Iovance Biotherapeutics had a negative return on equity of 49.71% and a negative net margin of 176.49%. The company had revenue of $49.32 million for the quarter, compared to the consensus estimate of $83.40 million. During the same period in the previous year, the firm earned ($0.42) earnings per share. The company’s revenue was up 6795.1% compared to the same quarter last year.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp grew its position in shares of Iovance Biotherapeutics by 7.4% during the 4th quarter. Northern Trust Corp now owns 2,414,807 shares of the biotechnology company’s stock valued at $17,870,000 after acquiring an additional 166,231 shares during the period. Wells Fargo & Company MN grew its stake in Iovance Biotherapeutics by 0.8% in the 4th quarter. Wells Fargo & Company MN now owns 580,245 shares of the biotechnology company’s stock valued at $4,294,000 after acquiring an additional 4,401 shares during the period. California State Teachers Retirement System grew its stake in Iovance Biotherapeutics by 7.3% in the 4th quarter. California State Teachers Retirement System now owns 203,241 shares of the biotechnology company’s stock valued at $1,504,000 after acquiring an additional 13,774 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Iovance Biotherapeutics by 4.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,989,340 shares of the biotechnology company’s stock valued at $14,721,000 after acquiring an additional 76,196 shares during the period. Finally, Vanguard Group Inc. grew its stake in Iovance Biotherapeutics by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 27,534,340 shares of the biotechnology company’s stock valued at $203,754,000 after acquiring an additional 220,373 shares during the period. Hedge funds and other institutional investors own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.